Steffel, J., Eikelboom, J. W., Anand, S. S., Shestakovska, O., Yusuf, S., & Fox, K. A. A. (2020). The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. Circulation (New York, N.Y.), 142(1), 40. https://doi.org/10.1161/CIRCULATIONAHA.120.046048
Citace podle Chicago (17th ed.)Steffel, Jan, John W. Eikelboom, Sonia S. Anand, Olga Shestakovska, Salim Yusuf, a Keith A A. Fox. "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease." Circulation (New York, N.Y.) 142, no. 1 (2020): 40. https://doi.org/10.1161/CIRCULATIONAHA.120.046048.
Citace podle MLA (9th ed.)Steffel, Jan, et al. "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease." Circulation (New York, N.Y.), vol. 142, no. 1, 2020, p. 40, https://doi.org/10.1161/CIRCULATIONAHA.120.046048.